Lab gears up to support COVID-19 trials
ACM Global Laboratories, a Rochester, NY company specializing in clinical trial testing services, currently supports studies in more than 65 countries around the world. Now, the company reports it has put in place specialized resources to better support clients conducting research on COVID-19 vaccines, treatments and other solutions.
ACM reportedly is boosting pandemic-related studies by offering special discounts and accelerated review process for COVID-19-centric studies.
“We at ACM Global Laboratories have the tools, ability and desire to make a difference,” said ACM chief commercial officer Thomas Mueller. “COVID-19 is affecting our communities and all who live in them. We are not only committed to using our resources to help defeat the virus but giving our communities the easiest and fastest means to do so, by prioritizing COVID-19 studies.”
A company representative told Outsourcing-Pharma its resources include “MD- and PhD-level” scientific and laboratory experts available to advise clients, as well as project managers, data management, quantitative expertise and other professionals. Additionally, its study support structure can customized sample and patient collection kits, dedicated project management, expert study set up, timely data reporting and integration, global logistics solutions and specimen management expertise and storage options.
The ACM team is available to conduct immunophenotypic analysis, support routine safety and bioanalytical study needs, coordinate and safely handle SARS CoV-2 PCR and serological antibody testing and provide guidance on vaccine assessment. It also offers state-of-the-art instruments and testing platforms, which are available to facilitate viral detection and perform assays to evaluate the safety and efficacy of vaccines and therapeutic interventions to treat COVID-19.
“ACM Global Laboratories’ extraordinary teams immediately responded to the need for support for COVID-19 clinical trials as the company has for nearly 25 years,” said ACM president Brian Wright. “When a global crisis happens, effective industry leaders like ACM don’t hesitate to be part of the solution and take actionable steps to mitigate the problem."
ACM is currently supporting a number of ongoing COVID-19 clinical studies underway plans to offer its support services to additional trials in the future.
